Clinical Outcomes of Abrocitinib in Prurigo Spectrum Disorders: A Case Series.

Prurigo simplex and prurigo nodularis are chronic, pruritic dermatoses with complex, cytokine-driven immunopathogenesis involving the JAK1-STAT signaling pathway. Real-world data on abrocitinib, a selective oral JAK1 inhibitor, in refractory pruritic dermatoses remain limited in the Indian population. Herein, we report four patients with prurigo spectrum disorders who were unresponsive to conventional therapies. Abrocitinib (100-200 mg once daily) resulted in rapid improvement in pruritus, followed by reduction in clinical lesions, including flattening of prurigo-like nodules, decreased pigmentation, and overall improvement in quality of life. No major adverse events were observed. These findings suggest that abrocitinib monotherapy may be an effective and well-tolerated option for refractory prurigo, warranting further evaluation in larger studies.